Search

Displaying results 2661 - 2670 of 8469 in total
  1. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.

  2. Drug

    Nisoxetine

    go.drugbank.com/drugs/DB09186
    Experimental

    It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI. … It has been used to research obesity and energy balance, and exerts some local analgesia effects.

  3. Drug

    Aldesleukin

    go.drugbank.com/drugs/DB00041
    ApprovedInvestigational

    for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. … This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon

  4. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.

  5. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.

  6. Drug

    Buserelin

    go.drugbank.com/drugs/DB06719
    ApprovedInvestigational

    Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.

  7. Drug

    Danegaptide

    go.drugbank.com/drugs/DB11821
    Investigational

    Danegaptide has been investigated for the treatment of Focus of Study is STEMI.

  8. Drug

    Piperacetazine

    go.drugbank.com/drugs/DB06808
    ApprovedVet approvedWithdrawn

    Piperacetazine was an antipsychotic.

  9. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

  10. Drug

    Alanine

    go.drugbank.com/drugs/DB00160
    ApprovedInvestigationalNutraceutical

    Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle...

    Mixtures: LEVAMIN PAD